Revance Therapeutics, Inc.
NASDAQ:RVNC
5.8 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Revance Therapeutics, Inc. |
Symbool | RVNC |
Munteenheid | USD |
Prijs | 5.8 |
Beurswaarde | 604,249,800 |
Dividendpercentage | 0% |
52-weken bereik | 2.3 - 9.745 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Mark J. Foley |
Website | https://www.revance.com |
An error occurred while fetching data.
Over Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)